A Phase 2 interventional study of Omecamtiv Mecarbil Matrix F1 Formulation and Omecamtiv Mecarbil Matrix F2 Formulation in Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction and Chronic Heart Failure, sponsored by Cytokinetics. Completed at 101 sites in 13 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-08-12.
Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Ventricular Dysfunction, Left with a site in United States — 15 open to participants now, 21 under way, 3 of them phase 3. Ventricular Dysfunction, Left · United States.
Among the 84 studies in Ventricular Dysfunction, Left with a site in United States, this one is the 9th largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2013, is one of 12 in phase 2, and was the 35th registered.
260 studies on the registry are indexed under Ventricular Dysfunction, Left; 57 are open to participants now.
Browse Ventricular Dysfunction, Left studies →15 of the 84 studies in Ventricular Dysfunction, Left with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 45–60 · Women only
Bayer · Sites in United States, Argentina, Austria and 20 more countries
Ages up to 18
Bayer · Sites in United States, Argentina, Austria and 20 more countries
Ages 6 mo–17 yrs
Mayo Clinic · Sites in United States
Ages 18+
Peerbridge Health, Inc · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Ventricular Dysfunction, Left studies recruiting now, 21 (55%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 11 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 544 is above the median of 100 across 151 interventional studies indexed under Ventricular Dysfunction, Left.
Median enrollment 87 across the 57 interventional studies, 307 across the 27 observational. Of the 58 that completed or were terminated, 29 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 84 have an industry lead sponsor. The 10 most frequent:
Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
Cytokinetics has 2 studies filed under Ventricular Dysfunction, Left — fewer than ten, so there is no comparison to draw.
4 of the studies in Ventricular Dysfunction, Left with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04752293Wake Forest University Health SciencesPediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE) | 2026-12 |
| NCT05388032Tulane UniversitySodium Lowering Vascular Effects Trial | 2026-12-31 |
| NCT01114269Brigham and Women's HospitalPRE-DETERMINE Cohort Study | 2027-11 |
| NCT06699056Peerbridge Health, IncAI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor | 2027-11-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies in Ventricular Dysfunction, Left with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic dysfunction and (ii) to characterize its pharmacokinetics (PK) over 20 weeks of treatment.
Omecamtiv mecarbil (AMG 423, CK-1827452) is a novel small molecule that increases cardiac contractility by selectively and directly activating the enzymatic domain of cardiac myosin heavy chain, the force-generating motor protein of the cardiac sarcomere. This is a randomized, placebo-controlled, multicenter, phase 2 study, consisting of a dose escalation phase to select 1 of 3 omecamtiv mecarbil oral formulations in 2 dose escalation cohorts, followed by an expansion phase to evaluate 20 weeks of administration of the selected omecamtiv mecarbil formulation at 2 target dose levels, compared with placebo.
This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo tablets twice a day (BID) for 7 days.
Drug: Placebo
Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days.
Drug: Omecamtiv Mecarbil Matrix F1 Formulation
Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days.
Drug: Omecamtiv Mecarbil Matrix F2 Formulation
Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days.
Drug: Omecamtiv Mecarbil Swellable Core Technology F2
Participants received placebo tablets twice a day for 7 days.
Drug: Placebo
Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days.
Drug: Omecamtiv Mecarbil Matrix F1 Formulation
Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days.
Drug: Omecamtiv Mecarbil Matrix F2 Formulation
Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days.
Drug: Omecamtiv Mecarbil Swellable Core Technology F2
Participants received placebo tablets twice a day for 20 weeks.
Drug: Placebo
Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks.
Drug: Omecamtiv Mecarbil Matrix F1 Formulation
All participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL.
Drug: Omecamtiv Mecarbil Matrix F1 Formulation
Modified release tablets for oral administration
Also known as: AMG 423, CK-1827452
Modified release tablets for oral administration
Also known as: AMG 423, CK-1827452
Modified release tablets matching to omecamtiv mecarbil
Modified release tablets for oral administration
Also known as: AMG 423, CK-1827452
Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)
Time frame: Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours, and 7 days post-dose.
Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)
Time frame: Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours, and 7 days post-dose.
Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7
Time frame: Day 7 at predose
Dose Escalation Phase: Area Under the Plasma Concentration-time Curve for a Dosing Interval of 12 Hours Post Dose (AUC12) for Omecamtiv Mecarbil
Time frame: Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose
Expansion Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing
Time frame: Predose (before morning dose) at weeks 2, 8, 12, 16, and 20
Expansion Phase: Maximum Observed Plasma Concentration of Omecamtiv Mecarbil
Time frame: Weeks 2 and 12 at predose and 1, 2, 4, 6, and 8 hours post-dose.
Expansion Phase: Change From Baseline in Systolic Ejection Time (SET) at Week 20
Systolic ejection time was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
Time frame: Baseline and week 20
Expansion Phase: Change From Baseline in Stroke Volume at Week 20
Stroke volume was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
Time frame: Baseline and week 20
Expansion Phase: Change From Baseline in Left Ventricular End Systolic Diameter (LVESD) at Week 20
LVESD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
Time frame: Baseline and week 20
Expansion Phase: Change From Baseline in Left Ventricular End Diastolic Diameter (LVEDD) at Week 20
LVEDD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
Time frame: Baseline and week 20
Expansion Phase: Change From Baseline in Heart Rate at Week 20
Heart rate was measured using electrocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
Time frame: Baseline and week 20
Expansion Phase: Change From Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP) at Week 20
Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
Time frame: Baseline and week 20
Dose Escalation Phase: Number of Participants With Treatment-emergent Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. Each adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event
Time frame: From first dose of study drug to 4 weeks after last dose; treatment duration was 7 days in the dose escalation phase.
Expansion Phase: Number of Participants With Treatment-emergent Adverse Events
An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. Each adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event
Time frame: From first dose of study drug until 4 weeks after last dose; treatment duration was 20 weeks in the expansion phase.
Participants with chronic heart failure treated with stable, optimal pharmacological therapy for ≥ 4 weeks were enrolled from February 2013 to March 2015 at 86 centers in 13 countries in Europe, Australia, and North America. The study consisted of a dose-escalation phase to select 1 of 3 omecamtiv mecarbil (OM) oral formulations in 2 dose cohorts, and an expansion phase to evaluate 20 weeks of treatment with the selected formulation at 2 target dose levels, compared with placebo.
| Milestone | Dose-escalation Cohort 1: Placebo | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Placebo | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 11 | 11 | 14 | 13 | 10 | 11 | 12 | 14 | 149 | 150 | 149 |
| Received study treatment | 11 | 10 | 14 | 13 | 10 | 11 | 11 | 14 | 149 | 150 | 146 |
| Completed | 11 | 10 | 14 | 13 | 10 | 11 | 11 | 14 | 145 | 145 | 137 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 5 | 12 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Decision by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 7 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 3 |
| ng/mL | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 |
|---|---|---|---|---|---|---|
| Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | 193 ± 58.8 | 201 ± 94.4 | 171 ± 53.8 | 492 ± 115 | 502 ± 138 | 601 ± 204 |
| hours | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 |
|---|---|---|---|---|---|---|
| Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) | 3.9 ± 4.4 | 2.0 ± 1.2 | 4.2 ± 1.9 | 2.6 ± 2.4 | 2.2 ± 1.8 | 4.6 ± 2.3 |
| ng/mL | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 |
|---|---|---|---|---|---|---|
| Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7 | 157 ± 63.7 | 137 ± 56.8 | 134 ± 54.7 | 376 ± 170 | 395 ± 108 | 476 ± 234 |
| ng*hr/mL | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 |
|---|---|---|---|---|---|---|
| Dose Escalation Phase: Area Under the Plasma Concentration-time Curve for a Dosing Interval of 12 Hours Post Dose (AUC12) for Omecamtiv Mecarbil | 2030 ± 658 | 2000 ± 1020 | 1740 ± 586 | 5070 ± 1060 | 5010 ± 1160 | 6550 ± 2340 |
| ng/mL | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|
| Week 2 | 174 ± 62.2 | 179 ± 68.8 |
| Week 8 | 156 ± 69.1 | 161 ± 74.4 |
| Week 12 | 165 ± 67.9 | 263 ± 116 |
| Week 16 | 155 ± 69.0 | 240 ± 120 |
| Week 20 | 149 ± 71.2 | 239 ± 118 |
| ng/mL | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|
| Week 2 | 212 ± 70.4 | 212 ± 81.0 |
| Week 12 | 200 ± 71.1 | 318 ± 129 |
Systolic ejection time was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
| seconds | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|---|
| Expansion Phase: Change From Baseline in Systolic Ejection Time (SET) at Week 20 | 0.0000 ± 0.0025 | 0.0112 ± 0.0024 | 0.0250 ± 0.0026 |
Stroke volume was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
| mL | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|---|
| Expansion Phase: Change From Baseline in Stroke Volume at Week 20 | -1.05 ± 1.18 | 3.53 ± 1.16 | 2.58 ± 1.19 |
LVESD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
| cm | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|---|
| Expansion Phase: Change From Baseline in Left Ventricular End Systolic Diameter (LVESD) at Week 20 | -0.242 ± 0.043 | -0.322 ± 0.044 | -0.421 ± 0.045 |
LVEDD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
| cm | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|---|
| Expansion Phase: Change From Baseline in Left Ventricular End Diastolic Diameter (LVEDD) at Week 20 | 0.089 ± 0.038 | 0.023 ± 0.038 | -0.040 ± 0.040 |
Heart rate was measured using electrocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
| bpm | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|---|
| Expansion Phase: Change From Baseline in Heart Rate at Week 20 | 0.57 ± 0.79 | -0.77 ± 0.79 | -2.40 ± 0.81 |
Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.
| pg/mL | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|---|
| Expansion Phase: Change From Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP) at Week 20 | 502 ± 257 | -319 ± 257 | -468 ± 262 |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. Each adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event
| Participants | Dose-escalation Cohort 1: Placebo | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Placebo | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 |
|---|---|---|---|---|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 4 | 2 | 6 | 6 | 1 | 9 | 3 | 5 |
| TEAE Grade ≥ 2 | 0 | 1 | 1 | 1 | 1 | 5 | 1 | 1 |
| TEAE Grade ≥ 3 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 1 |
| TEAE Grade ≥ 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Serious adverse events | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 1 |
| TEAE leading to discontinuation of study drug | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Fatal adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. Each adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event
| Participants | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 91 | 92 | 95 |
| TEAE Grade ≥ 2 | 62 | 60 | 61 |
| TEAE Grade ≥ 3 | 34 | 28 | 31 |
| TEAE Grade ≥ 4 | 5 | 8 | 11 |
| Serious adverse events | 30 | 36 | 32 |
| TEAEs leading to discontinuation of study drug | 12 | 8 | 12 |
| Fatal adverse events | 4 | 1 | 3 |
Collected over From first dose of study drug to 4 weeks after last dose; treatment duration was 7 days in the dose escalation phase and 20 weeks in the expansion phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose-escalation Cohort 1: Placebo | — | 0/11 (0%) | 4/11 (36.4%) |
| Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | — | 0/10 (0%) | 2/10 (20%) |
| Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | — | 1/14 (7.1%) | 5/14 (35.7%) |
| Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | — | 0/13 (0%) | 6/13 (46.2%) |
| Dose-escalation Cohort 2: Placebo | — | 0/10 (0%) | 1/10 (10%) |
| Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | — | 2/11 (18.2%) | 8/11 (72.7%) |
| Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | — | 0/11 (0%) | 3/11 (27.3%) |
| Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | — | 1/14 (7.1%) | 4/14 (28.6%) |
| Expansion Phase: Placebo | — | 30/149 (20.1%) | 48/149 (32.2%) |
| Expansion Phase: Omecamtiv Mecarbil 25 mg | — | 36/150 (24%) | 51/150 (34%) |
| Expansion Phase: OM PK-based Titration | — | 32/146 (21.9%) | 48/146 (32.9%) |
| Event | Dose-escalation Cohort 1: Placebo | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Placebo | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Angina unstableCardiac disorders | 0/11 | 0/10 | 0/14 | 0/13 | 0/10 | 1/11 | 0/11 | 0/14 | 0/149 | 1/150 | 1/146 |
| Myocardial ischaemiaCardiac disorders | 0/11 | 0/10 | 0/14 | 0/13 | 0/10 | 1/11 | 0/11 | 0/14 | 0/149 | 0/150 | 1/146 |
| CellulitisInfections and infestations | 0/11 | 0/10 | 1/14 | 0/13 | 0/10 | 0/11 | 0/11 | 0/14 | 0/149 | 1/150 | 2/146 |
| PneumoniaInfections and infestations | 0/11 | 0/10 | 0/14 | 0/13 | 0/10 | 0/11 | 0/11 | 1/14 | 1/149 | 1/150 | 3/146 |
| Cardiac failureCardiac disorders | 0/11 | 0/10 | 0/14 | 0/13 | 0/10 | 0/11 | 0/11 | 0/14 | 4/149 | 3/150 | 5/146 |
| Cardiac failure acuteCardiac disorders | 0/11 | 0/10 | 0/14 | 0/13 | 0/10 | 0/11 | 0/11 | 0/14 | 1/149 | 3/150 | 3/146 |
| Cardiac failure congestiveCardiac disorders | 0/11 | 0/10 | 0/14 | 0/13 | 0/10 | 0/11 | 0/11 | 0/14 | 3/149 | 3/150 | 3/146 |
| Cardiac failure chronicCardiac disorders | 0/11 | 0/10 | 0/14 | 0/13 | 0/10 | 0/11 | 0/11 | 0/14 | 3/149 | 0/150 | 0/146 |
| Angina pectorisCardiac disorders | 0/11 | 0/10 | 0/14 | 0/13 | 0/10 | 0/11 | 0/11 | 0/14 | 0/149 | 3/150 | 1/146 |
| Troponin increasedInvestigations | 0/11 | 0/10 | 0/14 | 0/13 | 0/10 | 0/11 | 0/11 | 0/14 | 0/149 | 2/150 | 2/146 |
| Event | Dose-escalation Cohort 1: Placebo | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Placebo | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/11 | 0/10 | 1/14 | 5/13 | 0/10 | 2/11 | 0/11 | 0/14 | 5/149 | 2/150 | 9/146 |
| AstheniaGeneral disorders | 0/11 | 1/10 | 3/14 | 0/13 | 0/10 | 0/11 | 1/11 | 0/14 | 2/149 | 2/150 | 2/146 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/11 | 0/10 | 0/14 | 0/13 | 0/10 | 2/11 | 0/11 | 0/14 | 0/149 | 0/150 | 1/146 |
| AnaemiaBlood and lymphatic system disorders | 0/11 | 0/10 | 0/14 | 0/13 | 1/10 | 0/11 | 0/11 | 0/14 | 1/149 | 0/150 | 0/146 |
| Bundle branch block leftCardiac disorders | 0/11 | 1/10 | 0/14 | 0/13 | 0/10 | 0/11 | 0/11 | 0/14 | 0/149 | 1/150 | 0/146 |
| Sinus tachycardiaCardiac disorders | 0/11 | 1/10 | 0/14 | 0/13 | 0/10 | 0/11 | 0/11 | 0/14 | 0/149 | 0/150 | 0/146 |
| Skin abrasionInjury, poisoning and procedural complications | 0/11 | 0/10 | 0/14 | 0/13 | 1/10 | 0/11 | 0/11 | 0/14 | 0/149 | 0/150 | 0/146 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/11 | 1/10 | 0/14 | 0/13 | 0/10 | 0/11 | 0/11 | 0/14 | 0/149 | 0/150 | 0/146 |
| HypotensionVascular disorders | 0/11 | 1/10 | 0/14 | 0/13 | 0/10 | 1/11 | 0/11 | 1/14 | 3/149 | 1/150 | 5/146 |
| FatigueGeneral disorders | 0/11 | 0/10 | 0/14 | 0/13 | 0/10 | 0/11 | 0/11 | 0/14 | 4/149 | 14/150 | 9/146 |
| Age, Continuous(years) | Dose-escalation Cohort 1: Placebo | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Placebo | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 66.5 ± 4.6 | 67.7 ± 11.4 | 65.3 ± 8.8 | 66.7 ± 8.7 | 62.1 ± 9.3 | 65.1 ± 7.0 | 63.8 ± 11.6 | 64.3 ± 11.5 | 63.7 ± 9.7 | 62.8 ± 10.2 | 62.7 ± 11.7 | 63.4 ± 10.4 |
| Age, Customized(Participants) | Dose-escalation Cohort 1: Placebo | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Placebo | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 - 64 years | 3 | 4 | 7 | 5 | 5 | 6 | 5 | 6 | 82 | 81 | 76 | 280 |
| 65 - 74 years | 8 | 4 | 4 | 6 | 5 | 4 | 4 | 5 | 46 | 52 | 50 | 188 |
| 75 - 84 years | 0 | 3 | 3 | 2 | 0 | 1 | 3 | 3 | 21 | 17 | 23 | 76 |
| Sex: Female, Male(Participants) | Dose-escalation Cohort 1: Placebo | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Placebo | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 3 | 1 | 3 | 3 | 4 | 2 | 30 | 23 | 24 | 97 |
| Male | 9 | 9 | 11 | 12 | 7 | 8 | 8 | 12 | 119 | 127 | 125 | 447 |
| Ethnicity (NIH/OMB)(Participants) | Dose-escalation Cohort 1: Placebo | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Placebo | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 7 | 4 | 17 |
| Not Hispanic or Latino | 11 | 10 | 14 | 12 | 9 | 11 | 11 | 14 | 147 | 143 | 145 | 527 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Dose-escalation Cohort 1: Placebo | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Placebo | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 3 |
| Black or African American | 3 | 1 | 0 | 0 | 0 | 3 | 1 | 2 | 11 | 5 | 8 | 34 |
| Mixed Race | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 7 | 10 | 14 | 12 | 10 | 8 | 11 | 12 | 136 | 142 | 140 | 502 |
| Other | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| Stratification Factor - Atrial Fibrillation/Flutter at Randomization(Participants) | Dose-escalation Cohort 1: Placebo | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2 | Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2 | Dose-escalation Cohort 2: Placebo | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2 | Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2 | Expansion Phase: Placebo | Expansion Phase: Omecamtiv Mecarbil 25 mg | Expansion Phase: OM PK-based Titration | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | 0 | 0 | 3 | 2 | 0 | 1 | 2 | 3 | 32 | 32 | 32 | 107 |
| No | 11 | 11 | 11 | 11 | 10 | 10 | 10 | 11 | 117 | 118 | 117 | 437 |
Showing the first 100 of 101 sites across 13 countries. Choose a country and city above to see the rest.
Ran from Feb 2013 to primary completion in Jul 2015, 28 months.
Results were first posted in May 2021, 5 years 9 months after primary completion. A results delay was requested in Mar 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omecamtiv mecarbil
Ventricular Dysfunction, Left →